Scott Rocklage’s idea to start 5AM Ventures is pretty literal to the firm’s name. He explains that just like five in the morning, 5AM Ventures is focused in the early stages of an enterprise’s establishment.
He spends his days dealing with both the business and scientific side of his firms. He does not have a standard nine to five with predetermined errands but instead he has prescheduled or impromptu tasks. Some days he attends board meetings while others are spent handling life science. Read more: Scott Rocklage | LinkedIn
Scott Rocklage works with a broad network of scientists, business experts and physicians who collaborate to make 5AM Ventures a birthplace for medicinal innovations. He is highly driven by the need to alienate suffering caused by cancer and works tirelessly to study genotypes and mutations that could lead to a breakthrough.
To maintain high productivity at work, Scott has learnt to integrate competitive professionals in all spheres of the business.
Scott’s portfolio displays his undeterred focus in the niche with a long list of achievements he has manifested over the years. Scott Rocklage has a bachelors in chemistry from MIT and a doctorate from the same institution.
He joined 5AM Ventures in 2003 as a managing partner and graduated to be the managing partner in 2004. He has performed intense research that led to the approval of three drugs by the FDA, namely, Cubicin, Omniscan, and Teslascan. Learn more about Scott Rocklage: http://www.rennovia.com/team/scott-m-rocklage/ and http://5amventures.com/team/scott-m-rocklage-phd/
Scott has an extensive experience in administration of medical institutions which affords him the expertise to lead 5AM Ventures to unchartered territory in the medical world. He previously served Cubist Pharmaceuticals as a chief executive and chairman.
He worked for Nycome Salutar as president and CEO and chairman at Relypsa and Novira. Currently he serves on the boards of Rennovia, Cidara, Kinestral, Pulmtarix and Epirus as chairman.
Scott Rocklage is the recipient of the 2005 Nobel Prize in Chemistry for his research at the Richard R. Schrock laboratory. He is a holder of more than 30 United States patents and is the author of over 100 peer review publications.
Scott values organized time and attributes his successes to the accurate anticipation of every tasks’s output.